Examination of this link was motivated by the findings of a phase II study of single‐agent everolimus in colorectal cancer (Di Nicolantonio et al., 2010), and response of colon cancer cell lines to the ATP‐competitive mTOR inhibitor PP242 (Ducker et al., 2014), which demonstrated an association between K‐Ras mutation status and resistance to mTOR inhibitors. This evidence concerns the gene KRAS and colorectal cancer.